10-Q: MiMedx Reports Q2 2026 Results, Surgical Growth Continues

MiMedx Group, Inc. announced its second quarter 2026 financial results, highlighting continued growth in its Surgical segment despite an overall revenue decline driven by its Wound care division.

Summary

• MiMedx Group, Inc. reported net sales of $64.4 million for the second quarter of 2026, a 34.7% decrease compared to the same period in 2025.
• The decline was primarily driven by a 61.1% drop in Wound segment sales, attributed to changes in Medicare reimbursement.
• The Surgical segment showed a 15.1% increase in net sales, reaching $39.3 million, marking its sixth consecutive quarter of double-digit year-over-year growth.
• The company reported a GAAP net loss of $14.8 million for the quarter, or $0.10 per diluted share, compared to a net income of $9.6 million in the prior year.
• Operating expenses were reduced, with Selling, General, and Administrative (SG&A) expenses decreasing by 6.8% to $59.8 million, and Research and Development (R&D) expenses down 15.9% to $2.8 million.
• The company ended the quarter with $135.8 million in cash and cash equivalents.
• MiMedx completed a reduction-in-force and implemented further cost-saving measures.
• The company repurchased approximately $13 million of its common stock under its Share Repurchase Plan.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline and net loss, despite positive performance in the Surgical segment and cost-saving measures.

Positives

• Surgical segment net sales increased by 15.1% to $39.3 million, demonstrating continued growth.
• The Surgical segment has achieved six consecutive quarters of double-digit year-over-year growth.
• Selling, General, and Administrative (SG&A) expenses decreased by 6.8% to $59.8 million.
• Research and Development (R&D) expenses decreased by 15.9% to $2.8 million.
• The company maintained a strong cash position with $135.8 million in cash and cash equivalents.
• The company is actively repurchasing shares under its Share Repurchase Plan, returning capital to shareholders.

Negatives

• Total net sales decreased by 34.7% to $64.4 million.
• Wound segment net sales decreased significantly by 61.1% to $25.1 million.
• Gross profit margin declined to 69.0% from 81.1% in the prior year.
• The company reported a GAAP net loss of $14.8 million for the quarter.
• Bad debt expense increased by $5.0 million due to credit deterioration of legacy customers.
• The company experienced a decrease in cash from operating activities by $27.9 million for the six-month period.

Risks

• Continued impact of Medicare reimbursement changes on Wound business pricing and sales volumes.
• Credit deterioration of certain legacy customers leading to increased bad debt expense.
• Potential for future litigation and regulatory matters to impact financial results.
• The company's disagreement with the FDA's determination regarding AXIOFILL's regulatory classification.
• Dependence on the success of new product launches and strategic initiatives.
• Potential for increased manufacturing costs impacting gross profit margins.

Future Outlook

The company expects to use capital to invest in broadening its product portfolio, including through potential acquisitions, licensing agreements, or other arrangements, international expansion, and certain capital projects. Management believes current cash reserves and available credit will meet operational liquidity needs for the next twelve months.

Management Comments

• "During the second quarter of 2026, we continued to execute our strategic priorities, including expanding our Surgical portfolio, launching new products, advancing recent cost reduction initiatives, and returning capital to shareholders through our Share Repurchase Plan."
• "These efforts contributed to continued growth in the Surgical business, which demonstrated a sixth consecutive quarter of double-digit year-over-year growth."
• "We reported a GAAP net loss of $15 million or $0.10 per diluted share, and ended the quarter with $136 million of cash and cash equivalents."
• "During the quarter, we completed a reduction-in-force and implemented additional cost reduction initiatives designed to align our cost structure with current business needs and support operating efficiency."
• "Separately, we repurchased approximately $13 million of common stock under our Share Repurchase Plan, reflecting our continued commitment to disciplined capital allocation and delivering long-term shareholder value."

Industry Context

StockSavvy.ai notes that MiMedx's performance reflects a challenging environment for companies reliant on Medicare reimbursement for wound care products, as evidenced by the significant decline in their Wound segment. However, the continued strong growth in the Surgical segment indicates a successful diversification strategy and market penetration in that area.

Comparison to Industry Standards

• The 61.1% decline in Wound segment sales due to Medicare reimbursement changes is a significant deviation from typical growth expectations in the healthcare sector, where stable or growing reimbursement is usually anticipated.
• The 15.1% growth in the Surgical segment is a positive outlier compared to many medical device companies experiencing slower growth in the current economic climate.
• The company's focus on cost reduction aligns with broader industry trends of operational efficiency and margin improvement, particularly for companies facing revenue headwinds.

Legal Proceedings

• The Company is a party to pending and threatened legal, regulatory, and governmental actions and proceedings.
• MiMedx filed suit against the FDA regarding the regulatory classification of AXIOFILL, with the court denying summary judgment motions and requesting additional briefing.

Stakeholder Impact

• Shareholders: The net loss and revenue decline may negatively impact share price, while share repurchases could provide some support.
• Employees: A reduction-in-force was completed, indicating potential job impacts.
• Customers: Changes in Medicare reimbursement may affect the accessibility or cost of wound care products.
• Suppliers: No specific impact mentioned, but overall company performance could influence future business relationships.

Next Steps

• Continue executing strategic priorities, including expanding the Surgical portfolio and launching new products.
• Advance cost reduction initiatives to align cost structure with business needs and support operating efficiency.
• Continue returning capital to shareholders through the Share Repurchase Plan.
• Monitor and adapt to changes in Medicare reimbursement for wound care products.
• Proceed with the acquisition of Sanara MedTech Inc., anticipated to close in 2026.
• Prepay the remaining $17.3 million outstanding principal balance of the Citizens Term Loan.

Key Dates

Recommendation

The company shows resilience with strong growth in its Surgical segment and effective cost management, but the significant decline in its Wound segment and the resulting net loss warrant a cautious 'hold' rating. The pending acquisition of Sanara MedTech could be a catalyst, but execution risk remains.

Keywords

Wound Care, Surgical Products, Medicare Reimbursement, Financial Results, Revenue Decline, Cost Reduction, Share Repurchase, FDA Warning Letter